Clinical trial
A Phase 1 Study in Chronic Hepatitis B Participants to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-171
NCT07617194 is registered in ClinicalTrials.gov with AusperBio Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study in Chronic Hepatitis B Participants to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-171
- Lead sponsor
- AusperBio Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- July 6, 2026
- Completion date
- August 14, 2028
- Enrollment
- 144 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.